Date: 2015-11-26
Type of information: Capital increase
Company: Immunovia (Sweden)
Investors:
Amount: SEK 60 million (€ 6.5 million)
Funding type: capital increase
Planned used:
Others: * On November 26th, 2015, Immunovia has been approved for trading of its shares on Nasdaq First North in Stockholm. The first trading day is December 1st, 2015. A new share issue of SEK 60 million before issue costs have been carried out before introduction on First North. With this approval, shares will be available for trading on December 1st. Prior to the introduction on First North, Immunovia carried out a new share issue that was oversubscribed five times. The share issue period ended November 16th, 2015 and provided the company with SEK 60 million before issue costs and about 1 100 new shareholders. * On November 19th, 2015, Immunovia announced that its new share issue prior to listing on Nasdaq First North was subscribed to SEK 305 million, representing a subscription rate of 500 percent. The issue provides the Company with SEK 60 million before transaction costs and about 1100 new shareholders. First day of trading of the Company’s shares on Nasdaq First North in Stockholm is expected to be 1 December 2015. The subscription period for Immunovia’s share issue expired on November 16, 2015. Already before the subscription period began, a number of existing and new investors, including the Bank of Åland’s Fund Management Division together with several international investors, had committed to subscribe for shares in the issue totaling close to SEK 50 million or approximately 83 per cent of the offer. These investors were then given priority when shares were allocated. However, the overall goal of the share issue remained to obtain a broad distribution of shares among the public in Sweden in order to allow regular and liquid trading of Immunovia’s shares on Nasdaq First North. After the new share issue has been registered at Bolagsverket (the Swedish Companies Registration Office), the total number of shares in Immunovia increased by 3,245,000 to 14,291,216 representing an increase of the share capital and votes of 29 percent.
Therapeutic area: Cancer - Oncology - Diagnostic
